Develops targeted microProtein therapeutics that reprogram transcriptional profiles by modulating pioneer transcription factors and master regulators. Applies functional analysis, knowledge‑based design and rigorous experimental validation to create tailored treatments for diseases driven by dysregulated master regulators, such as cancer.